PV Bulletin

MHRA Guidance on Ambient Voice Technology Classification

The MHRA clarifies the regulatory status of ambient voice technology used in healthcare, distinguishing between tools requiring regulation as medical devices and those that do not.

Primary source: Medicines and Healthcare products Regulatory Agency

PV Impact Brief

Urgency: HighConfidence: high

What changed

Manufacturers and NHS organizations must classify AVT products based on intended use, with transcription tools not regulated as medical devices, while those supporting diagnosis or treatment must comply with medical device regulations.

Why it matters

This guidance provides critical clarity on the regulatory framework for AVT tools, facilitating safer implementation within the NHS and ensuring that products are appropriately classified for compliance.

Action needed

PV and device vigilance teams need to review their AVT product portfolios to verify correct classification and ensure adherence to medical device vigilance reporting workflows, especially for those tools classified as medical devices.

Relevant for
Regulatory Intelligence LeadPV Quality LeadQPPV
Processes impacted
Inspection ReadinessCountry Compliance
Owner

Regulatory Intelligence Lead

Review cadence

Quarterly or as relevant changes arise

Policy change details

Document type
Guideline
Policy status
Final
Publication date
2026-07-29
Policy change
The MHRA has issued guidance clarifying the regulatory status of ambient voice technology (AVT) used in healthcare. The guidance distinguishes between tools used solely for transcription and clinical documentation (not regulated as medical devices) and tools used for diagnosis, prevention, or treatment (regulated as medical devices). It clarifies how existing medical device laws apply to these AI-driven tools.

Affected workflows

Inspection ReadinessCountry Compliance

Responsible groups

Digital Health TeamsVigilance OperationsLegal/Compliance

PV impact

Manufacturers and NHS organizations must evaluate their AVT products against these classification criteria. If a tool is classified as a medical device, it must comply with medical device vigilance reporting requirements, including adverse incident reporting. PV and device vigilance teams should review their portfolios of digital health tools to ensure correct classification and reporting workflows are in place.

View regulator source

Source document details

Exact policy details

Regulatory Clarification
AVT products solely intended for transcription or summarising clinical conversations are not regulated as medical devices.
Applies to: Applicable to AVT products used in health and care settings in Great Britain.
The guidance confirms that those AVT products that are intended solely for transcription, summarising of clinical conversations, drafting letters, or suggesting clinical codes for a clinician to review are not regulated as medical devices under the current framework. · p. 1 · High · Source
Regulatory Requirements
AVT products that support diagnosis or treatment, or that take automated action without clinician review, are regulated as medical devices.
Applies to: AVT products with diagnostic or therapeutic intent.
AVT products intended to support diagnosis, treatment or prevention, or that take automated action such as placing orders without clinician review, are regulated as medical devices and must meet the relevant safety and performance requirements. · p. 1 · High · Source
Clinical Oversight Assurance
NHS boards and executive teams must assure that AVT deployment is supported by appropriate clinical oversight.
Applies to: Applicable to NHS organizations implementing AVT products.
NHS boards and executive teams are asked to assure themselves that AVT deployment is supported by appropriate clinical oversight, local governance, staff training and procurement processes. · p. 1 · High · Source

Evidence and confidence

Confidence: highSource updated: Jul 29, 2026

Full briefing

Practical implication

PV and device vigilance teams need to review their AVT product portfolios to verify correct classification and ensure adherence to medical device vigilance reporting workflows, especially for those tools classified as medical devices.

The Medicines and Healthcare products Regulatory Agency (MHRA) has published guidance regarding ambient voice technology (AVT) products used in health settings. This guidance differentiates between AVT products solely for transcription (not regulated) and those for diagnosis, treatment, or prevention (regulated). Manufacturers must evaluate their AVT products accordingly to ensure compliance with medical device vigilance reporting requirements.

What changed: Manufacturers and NHS organizations must classify AVT products based on intended use, with transcription tools not regulated as medical devices, while those supporting diagnosis or treatment must comply with medical device regulations.

Why it matters: This guidance provides critical clarity on the regulatory framework for AVT tools, facilitating safer implementation within the NHS and ensuring that products are appropriately classified for compliance.

Practical implication: PV and device vigilance teams need to review their AVT product portfolios to verify correct classification and ensure adherence to medical device vigilance reporting workflows, especially for those tools classified as medical devices.

View original source

Published from the Firecrawl policy change extraction pipeline.

Related updates for your role

publicFDA · USA · Updated Sep 4, 2026

FDA Grants Accelerated Approval to Etcamah for Advanced Breast Cancer

Urgency: High

Regulatory teams must prepare for updating labeling to include details on the new indication and required diagnostic methods, along with planning for the confirmatory studies mandated by the FDA.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicMHRA · UK · Updated Sep 4, 2026

Change to the definition of regulated activity with children from 1 September 2026

Urgency: High

Organizations must re-evaluate roles related to children's activities and prepare to request Enhanced DBS checks including access to the Children’s Barred List check starting from 1 September 2026.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicUK Health Security Agency · UK · Updated Sep 7, 2026

Low Flu Vaccination Rates Among Primary School Children

Urgency: High

Parents are reminded to complete and return flu vaccination consent forms promptly as vaccination sessions in schools are set to start this week, aiming for completion by late November.

Signal ManagementPV Quality Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: PV Quality Lead, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Recall of Gore Viabahn Endoprosthesis with Bioactive Heparin Coating

Urgency: High

Health establishments receiving affected devices must be notified, and protocols established to ensure compliance with the recall.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward